Publikationen
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H. U., Popescu, A. C., Burnett, A., Mills, K., Casero, R. A., Jr, Marton, L., Woster, P., Minden, M. D., Dugas, M., Wang, J. C., Dick, J. E., Müller-Tidow, C., Petrie, K., & Zelent, A. (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature medicine, 18(4), 605–611. https://doi.org/10.1038/nm.2661
Schenk, T., Stengel, S., & Zelent, A. (2014). Unlocking the potential of retinoic acid in anticancer therapy. British journal of cancer, 111(11), 2039–2045. https://doi.org/10.1038/bjc.2014.412
Göllner, S., Oellerich, T., Agrawal-Singh, S., Schenk, T., Klein, H. U., Rohde, C., Pabst, C., Sauer, T., Lerdrup, M., Tavor, S., Stölzel, F., Herold, S., Ehninger, G., Köhler, G., Pan, K. T., Urlaub, H., Serve, H., Dugas, M., Spiekermann, K., Vick, B., … Müller-Tidow, C. (2017). Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nature medicine, 23(1), 69–78. https://doi.org/10.1038/nm.4247
Steube, A., Schenk, T., Tretyakov, A., & Saluz, H. P. (2017). High-intensity UV laser ChIP-seq for the study of protein-DNA interactions in living cells. Nature communications, 8(1), 1303. https://doi.org/10.1038/s41467-017-01251-7
Kahl, M., Brioli, A., Bens, M., Perner, F., Kresinsky, A., Schnetzke, U., Hinze, A., Sbirkov, Y., Stengel, S., Simonetti, G., Martinelli, G., Petrie, K., Zelent, A., Böhmer, F. D., Groth, M., Ernst, T., Heidel, F. H., Scholl, S., Hochhaus, A., & Schenk, T. (2019). The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia, 33(11), 2628–2639. https://doi.org/10.1038/s41375-019-0581-y
Sbirkov, Y., Ivanova, T., Burnusuzov, H., Gercheva, K., Petrie, K., Schenk, T., & Sarafian, V. (2021). The Protozoan Inhibitor Atovaquone Affects Mitochondrial Respiration and Shows In Vitro Efficacy Against Glucocorticoid-Resistant Cells in Childhood B-Cell Acute Lymphoblastic Leukaemia. Frontiers in oncology, 11, 632181. https://doi.org/10.3389/fonc.2021.632181
Stengel, S., Petrie, K. R., Sbirkov, Y., Stanko, C., Ghazvini Zadegan, F., Gil, V., Skopek, R., Kamiński, P., Szymański, Ł., Brioli, A., Zelent, A., & Schenk, T. (2022). Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia. British journal of haematology, 198(2), 338–348. https://doi.org/10.1111/bjh.18187
Sbirkov, Y., Schenk, T., Kwok, C., Stengel, S., Brown, R., Brown, G., Chesler, L., Zelent, A., Fuchter, M. J., & Petrie, K. (2023). Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells. Frontiers in cell and developmental biology, 11, 1076458. https://doi.org/10.3389/fcell.2023.1076458
